Quick Answer
GYRE THERAPEUTICS, INC. reported Research And Development Expense of $13.70 million for the year ending 2025.
- GYRE THERAPEUTICS, INC. showed an increase of +13.9% in Research And Development Expense from 2024 to 2025.
- This data is from GYRE THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2009 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2009 to 2025), GYRE THERAPEUTICS, INC.'s Research And Development Expense has declined by 65.9%.
- Historical annual values: Fiscal year 2025: $13.70 million | Fiscal year 2024: $12.02 million | Fiscal year 2023: $13.78 million | Fiscal year 2021: $68.89 million | Fiscal year 2020: $52.98 million | Fiscal year 2019: $43.86 million | Fiscal year 2018: $21.47 million | Fiscal year 2017: $12.85 million | Fiscal year 2016: $11.56 million | Fiscal year 2015: $5.96 million | Fiscal year 2014: $5.27 million | Fiscal year 2013: $6.56 million | Fiscal year 2012: $49.09 million | Fiscal year 2011: $95.22 million | Fiscal year 2010: $64.55 million | Fiscal year 2009: $40.18 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: